vTv Therapeutics (NASDAQ:VTVT) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of vTv Therapeutics (NASDAQ:VTVT) from a buy rating to a sell rating in a research report report published on Saturday morning.

A number of other research analysts have also issued reports on VTVT. Zacks Research lowered shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. BTIG Research upped their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They set a “buy” rating and a $67.00 price target for the company. Weiss Ratings raised vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Finally, HC Wainwright dropped their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Stock Down 3.1%

Shares of VTVT stock opened at $34.29 on Friday. vTv Therapeutics has a 12 month low of $14.00 and a 12 month high of $44.00. The business’s 50 day moving average is $33.40 and its two-hundred day moving average is $34.81. The company has a market cap of $135.10 million, a PE ratio of -32.35 and a beta of 0.29.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). As a group, equities analysts expect that vTv Therapeutics will post -2.52 EPS for the current fiscal year.

Hedge Funds Weigh In On vTv Therapeutics

Large investors have recently bought and sold shares of the stock. 683 Capital Management LLC acquired a new stake in vTv Therapeutics in the 4th quarter worth $731,000. Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics during the fourth quarter valued at about $221,000. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.